Identification and validation of a plasma metabolomics-based model for risk stratification of intrahepatic cholangiocarcinoma

Background Liver resection is the mainstay of curative treatment for intrahepatic cholangiocarcinoma (ICC) while the postoperative prognosis varies greatly, with no recognized biomarker. We aimed to identify the plasma metabolomic biomarkers that could be used for preoperative risk stratification of ICC patients. Methods 108 eligible ICC patients who underwent radical surgical resection between August 2012 and October 2020 were enrolled. Patients were randomly divided into a discovery cohort (n = 76) and a validation cohort (n = 32) by 7:3. Metabolomics profiling of preoperative plasma was performed and clinical data were collected. The least absolute shrinkage and selection operator (LASSO) regression, Cox regression, and receiver operating characteristic (ROC) analyses were used to screen and validate the survival-related metabolic biomarker panel and construct a LASSO-Cox prediction model. Results 10 survival-related metabolic biomarkers were used for construction of a LASSO-Cox prediction model. In the discovery and validation cohorts, the LASSO-Cox prediction model achieved an AUC of 0.876 (95%CI: 0.777–0.974) and 0.860 (95%CI: 0.711–1.000) in evaluating 1-year OS of ICC patients, respectively. The OS of ICC patients in the high-risk group was significantly worse than that in the low-risk group (discovery cohort, p < 0.0001; validation cohort: p = 0.041). Also, the LASSO-Cox risk score (HR 2.43, 95%CI: 1.81–3.26, p < 0.0001) was a significant independent risk factor associated with OS. Conclusions The LASSO-Cox prediction model has potential as an important tool in evaluating the OS of ICC patients after surgical resection and can be used as prediction tools to implement the best treatment options that could result in better outcomes..

Medienart:

E-Artikel

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Zur Gesamtaufnahme - volume:149

Enthalten in:

Journal of cancer research and clinical oncology - 149(2023), 13 vom: 12. Juli, Seite 12365-12377

Sprache:

Englisch

Beteiligte Personen:

Tan, Jiehui [VerfasserIn]
Shu, Man [VerfasserIn]
Liao, Junbin [VerfasserIn]
Liang, Ruiming [VerfasserIn]
Liu, Shiyi [VerfasserIn]
Kuang, Ming [VerfasserIn]
Peng, Sui [VerfasserIn]
Xiao, Han [VerfasserIn]
Zhou, Qian [VerfasserIn]

Links:

Volltext [lizenzpflichtig]

BKL:

44.81$jOnkologie

Themen:

Intrahepatic cholangiocarcinoma
Metabolomics
Prognosis
Risk stratification

RVK:

RVK Klassifikation

Anmerkungen:

© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

doi:

10.1007/s00432-023-05119-w

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

OLC2145279601

Zugang & Verfügbarkeit




Zugehörige Publikationen/Bände

    Haven't found what you're looking for?